Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults
Hashimoto
About this trial
This is an interventional supportive care trial for Hashimoto focused on measuring Hashimoto, Autoimmune thyroiditis, Eye Movement Desensitization adn Reprocessing, Trauma
Eligibility Criteria
Inclusion Criteria:
- aged 18-55 years;
- confirmed autoimmune thyroiditis diagnosis
- at least one biological marker Anti-thyroid peroxidase (anti-TPO) antibodies or thyroglobulin antibodies (TgAb) exceeds the reference range
Exclusion Criteria:
- the presence of psychotic symptoms
- currently receiving another form of psychological treatment;
- under psychotropic medication;
- neurodevelopmental disorders (intellectual disability, communication disorders, autism spectrum disorders, ADHD);
- neurocognitive disorders;
- substance abuse;
- serious legal or health issues that would prevent from regularly attending
- patients with autoimmune thyroiditis with biological markers within the reference range
Sites / Locations
- University of Bucharest
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Active Comparator
Eye Movement Desensitization and Reprocessing
Placebo
Treatment as Usual
30 participants will be randomly allocated to the EMDR group. They will receive a 90 minutes session of EMDR each week for twelve weeks. The sessions will be conducted by clinicians or psychotherapists specialized in EMDR, and the participants will be randomly allocated to them. EMDR is a structured, goal-oriented, short-term intervention organized around traumatic or stressful memories. This method was discovered in 1981 by F. Shapiro and represented an evidence-based treatment, one of the two first-line trauma treatment recommended for use with adults (NICE, 2005; World Health Organization, 2013). EMDR proved effective by hundreds of researches and has also been shown to be useful in alleviating physical symptoms such as pain or increased autonomic activity. But to our knowledge, research on EMDR efficacy in the treatment of autoimmune thyroiditis has not been previously reported.
30 participants will be randomized to the placebo group. The placebo goup will receive an intervention that does not include working on past traumatic memories, it will be more focused on present and future.
30 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.